Acquired Autoimmune Hemolytic Anemia Market Size Forecasted To Achieve 2.88 Billion By 2029 With Steady Growth

"Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Acquired Autoimmune Hemolytic Anemia Market Size and Projected Growth Rate?
The market size for acquired autoimmune hemolytic anemia has seen a significant surge in recent times. The market, which is projected to be worth $2.01 billion in 2024, is set to increase to $2.16 billion in 2025, showing a compound annual growth rate (CAGR) of 7.5%. This robust growth experienced in the historic period is a result of a myriad of factors including escalated diagnosis rates, a rise in incidences of secondary AIHA, an enlargement in hospital hematology sections, backing from government and regulations, as well as growth in investments made in the field of hematology.

The market size of acquired autoimmune hemolytic anemia is forecasted to undergo robust expansion in the coming years, reaching $2.88 billion by 2029 at a compound annual growth rate (CAGR) of 7.4%. This prospective growth in the forecast period can be accredited to factors such as the escalating occurrence of autoimmune conditions, an enhanced comprehension of the pivotal role of the complement system, an increased partnership between biopharma and scholarly establishments, the rising implementation of bespoke treatments, and the growth of the elderly population. Predominant trends expected to emerge during the forecast period include the adoption of targeted biologic therapies, progress in complement pathway inhibitors, application of AI and data analytics in disease management, AI-driven clinical trial structuring, and innovation concerning orphan drugs.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24132&type=smp

What Are the Major Segments in the Acquired Autoimmune Hemolytic Anemia Market?
The acquired autoimmune hemolytic anemia market covered in this report is segmented -

1) By Diagnosis Method: Complete Blood Count, Peripheral Blood Smear, Direct Coombs Test, Indirect Coombs Test
2) By Treatment Type: Corticosteroids, Immunosuppressive Agents, Intravenous Immunoglobulin, Rituximab
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Specialty Clinics, Research Institutions

Subsegment:
1) By Complete Blood Count: Hemoglobin Level, Hematocrit (HCT), Reticulocyte Count, White Blood Cell Count, Platelet Count
2) By Peripheral Blood Smear: Spherocytes, Polychromasia, Schistocytes, Increased Reticulocyte Count
3) By Direct Coombs Test: Immunoglobulin G Coombs Test, Immunoglobulin M Coombs Test, Complement Coombs Test
4) By Indirect Coombs Test: Screening For Alloantibodies, Detection Of Sensitizing Antibodies, Crossmatch Testing

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24132&type=smp

What Are The Driving Acquired Autoimmune Hemolytic Anemia Market Evolution?
The escalating incidences of autoimmune disorders are anticipated to drive the expansion of the acquired autoimmune hemolytic anemia market. These disorders occur when the body's own immune system mistakenly attacks healthy cells and tissues, thinking they're harmful invaders. The surge in these conditions is often linked to an increase in environmental triggers and lifestyle changes that may impair the regulation of the immune system. As the prevalence of autoimmune disorders rises, there is also a higher incidence of acquired autoimmune hemolytic anemia. This is because individuals with autoimmune diseases are more prone to developing secondary AIHA due to impaired immune regulation. For instance, as per the autoimmune registry data in 2022, a US-based organization dedicated to collecting and analyzing information on autoimmune disorders, the percentage of patients diagnosed with multiple autoimmune conditions rose from 52% in 2021 to 55% in 2022. As a result, the escalating incidence of autoimmune disorders is anticipated to stimulate the growth of the acquired autoimmune hemolytic anemia market.

Which Firms Dominate The Acquired Autoimmune Hemolytic Anemia Market Segments?
Major companies operating in the acquired autoimmune hemolytic anemia market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi SA, Novartis AG, Amgen Inc., Incyte Corporation, Alexion Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Nanjing IASO Biotherapeutics Co. Ltd., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Zenas BioPharma Inc., Immunovant Sciences GmbH, Alpine Immune Sciences Inc., Agios Pharmaceuticals Inc., Rakshi*t Drugs Private Limited, Aarti Pharmalabs Ltd.

What Trends Are Expected to Dominate the Acquired Autoimmune Hemolytic Anemia Market in the Next 5 Years?
Leading companies in the acquired autoimmune hemolytic anemia market are turning their focus towards innovative targeted therapies, such as humanized monoclonal antibodies, to boost the effectiveness of treatments, lessen adverse effects, and offer more personalized patient care. Humanized monoclonal antibodies are lab-created proteins that imitate human antibodies, incorporating chiefly human components but also small segments of non-human (typically mouse) antibodies to optimize antigen targeting while reducing immune system rejection. For instance, Sanofi, a healthcare firm based in France, was granted approval by the U.S. Food and Drug Administration (FDA) in February 2022 for Enjaymo (sutimlimab-jome), making it the first and only approved treatment for cold agglutinin disease (CAD), a rare form of autoimmune hemolytic anemia. This drug functions by selectively blocking C1s in the classical complement pathway, preventing the immune system from assaulting and eliminating healthy red blood cells, thereby diminishing the necessity for red blood cell transfusions in CAD patients. Enjaymo specifically focuses on stemming C1-activated hemolysis without impacting the lectin or alternative complement pathways.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/acquired-autoimmune-hemolytic-anemia-global-market-report

Which Is The Largest Region In The Acquired Autoimmune Hemolytic Anemia Market?
North America was the largest region in the acquired autoimmune hemolytic anemia market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired autoimmune hemolytic anemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Acquired Autoimmune Hemolytic Anemia Market?
2. What is the CAGR expected in the Acquired Autoimmune Hemolytic Anemia Market?
3. What Are the Key Innovations Transforming the Acquired Autoimmune Hemolytic Anemia Industry?
4. Which Region Is Leading the Acquired Autoimmune Hemolytic Anemia Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments."

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
•LinkedIn: https://in.linkedin.com/company/the-business-research-company
•Twitter: https://twitter.com/tbrc_info
•YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.